CUDC-907 is primarily utilized in cancer research and therapy due to its dual inhibitory action on both histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K) pathways. This unique mechanism makes it effective in targeting cancer cells that rely on these pathways for growth and survival. It is being investigated for its potential in treating various cancers, including solid tumors and hematologic malignancies. By simultaneously blocking HDAC and PI3K, CUDC-907 disrupts cancer cell proliferation, induces apoptosis, and enhances the efficacy of other anticancer treatments. Its application is particularly promising in cases where resistance to conventional therapies has developed. Clinical trials are ongoing to evaluate its safety, tolerability, and therapeutic potential in human patients.